BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26883786)

  • 1. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
    Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
    BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden.
    Norlin JM; Carlsson KS; Persson U; Schmitt-Egenolf M
    BioDrugs; 2015 Dec; 29(6):389-98. PubMed ID: 26670179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register.
    Hjalte F; Carlsson KS; Schmitt-Egenolf M
    Br J Dermatol; 2018 Jan; 178(1):245-252. PubMed ID: 28644904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Dermatology; 2012; 225(4):326-32. PubMed ID: 23328678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
    Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
    Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis.
    Norlin JM; Löfvendahl S; Schmitt-Egenolf M
    J Clin Med; 2023 Nov; 12(23):. PubMed ID: 38068286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients.
    Norlin JM; Steen Carlsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2012 Apr; 166(4):797-802. PubMed ID: 22182212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study.
    Loft ND; Egeberg A; Rasmussen MK; Bryld LE; Gniadecki R; Dam TN; Iversen L; Skov L
    Acta Derm Venereol; 2019 Dec; 99(13):1224-1230. PubMed ID: 31580465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: A Register-Based Study of 4168 Patients.
    Calara PS; Althin R; Carlsson KS; Schmitt-Egenolf M
    BioDrugs; 2017 Feb; 31(1):75-82. PubMed ID: 28097638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.
    Geale K; Henriksson M; Schmitt-Egenolf M
    Br J Dermatol; 2016 Mar; 174(3):579-87. PubMed ID: 26616003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent.
    Hjalte F; Steen Carlsson K; Schmitt-Egenolf M
    Dermatology; 2015; 230(4):347-53. PubMed ID: 25721571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.
    Hägg D; Eriksson M; Sundström A; Schmitt-Egenolf M
    PLoS One; 2013; 8(5):e63619. PubMed ID: 23691076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization.
    Armstrong AW; Foster SA; Comer BS; Lin CY; Malatestinic W; Burge R; Goldblum O
    BMC Dermatol; 2018 Jun; 18(1):4. PubMed ID: 29954363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
    Al-Mutairi N; Nour T
    Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.